GlassScriptPhysician profile
Michael Anthony Orsini
NPI 1548235112
$4,704.61
in general payments reported to CMS, 2019-2025
24 companies · $888 in 2025
The $888 reported for 2025 was more than what 77% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $807 · 2020: $349 · 2021: $663 · 2022: $605 · 2023: $849 · 2024: $543 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,279.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $927.29 | 2020-2025 | Nucala |
| Optinose US, INC. | $740.21 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $647.66 | 2019-2025 | Dupixent |
| Genzyme Corporation | $377.50 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $374.87 | 2025 | Neffy |
| Novo Nordisk INC | $280.92 | 2019-2024 | |
| Csl Behring | $234.09 | 2019-2024 | Haegarda |
| Acadia Pharmaceuticals INC | $194.56 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $181.63 | 2021 | |
| Kaleo, INC. | $160.24 | 2019-2024 | Auvi-Q |
| Edwards Lifesciences Corporation | $116.14 | 2024 | |
| Phathom Pharmaceuticals, INC. | $97.87 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $82.17 | 2019 | |
| Alk-Abello, INC | $64.00 | 2019-2020 | |
| Abbvie INC. | $43.40 | 2023-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $33.25 | 2019 | |
| Ambu INC. | $29.88 | 2020 | |
| Jubilant Hollisterstier LLC | $23.35 | 2025 | |
| Organogenesis INC. | $21.26 | 2021 | |
| Hikma Pharmaceuticals USA | $18.24 | 2024 | Ryaltris |
| Phadia US INC. | $16.95 | 2024 | Immunocap |
| Greer Laboratories, INC. | $13.61 | 2019 | |
| Merck Sharp & Dohme LLC | $13.43 | 2021 | |
| Horizon Therapeutics Plc | $12.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Orsini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.